We describe an unusual case of chronic myelomonocytic leukemia with severe eosinophilia having t(5;12)(q31;p13) with t(1;7)(q10;p10). The eosinophilic proliferation was severe in peripheral blood and bone marrow, and they revealed marked dysplastic features. We performed fluorescence in situ hybridization (FISH) and immunohistochemistry to evaluate the clonality of eosinophils. The eosinophils were stained positively to platelet-derived growth factor receptor-β. By FISH using chromosome 1 satellite probe and chromosome 1q telomere probe, the eosinophils were proved to belong to the malignant clone.

Keywords:
Chronic myelomonocytic leukemia, Eosinophilia, Platelet-derived growth factor receptor-β, t(1;7), t(5;12)
1.
Bain BJ: Eosinophilic leukemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996;95:2–9.
2.
Keene P, Mendelow B, Pinto MR, Bezwoda W, MacDougall L, Falkson G, Ruff P, Bernstein R: Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: A nonrandom association. Br J Haematol 1987;67:25–31.
3.
Baranger L, Sazpiro N, Gardais J, Hillion J, Derre J, Francois S, Blanchet O, Boasson M, Berger R: Translocation t(5;12)(q31-q33;p12-p13): A non-random translocation associated with a myeloid disorder with eosinophilia. Br J Haematol 1994;88:343–347.
4.
Jani K, Kempski HM, Reeves RB: A case of myelodysplasia with eosinophilia having a translocation t(5;12)(q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol 1994;87:57–60.
5.
Bain BJ: Leukaemia Diagnosis, ed 3. Oxford, Blackwell, 2003.
6.
Wlodarska I, Mecucci C, Marynen P, Guo C, Franckx D, La Starza R, Aventin A, Bosly A, Martelli MF, Cassiman JJ, Van den Berghe H: TEL gene is involved in myelodysplastic syndrome with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). Blood 1995;85:2848–2852.
7.
Yoon S, Tefferi A, Li C: Cellular distribution of platelet-derived growth factor, transforming growth factor-β, basic fibroblast growth factor, and their receptors in normal bone marrow. Acta Haematol 2000;104:151–157.
8.
Steer EJ, Cross NCP: Myeloproliferative disorders with translocations of chromosome 5q31–35: Role of the platelet-derived growth factor receptor beta. Acta Haematol 2002;107:113–122.
9.
Magnusson MK, Meade KE, Nakamura R, Barrett J, Dunbar CE: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood 2002;100:1088–1091.
10.
Ma SK, Wong KF, Chan JKC, Kwong YL: Refractory cytopenia with t(1;7),+8 abnormality and dysplastic eosinophils showing intranuclear Charcot-Leyden crystals: A fluorescence in situ hybridization study. Br J Haematol 1995;90:216–218.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.